| 2022 | Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors | 권영주; 전경화 | Article |
| 2023 | Cervi Parvum Cornu complex for men with lower urinary tract symptoms: a multicenter, randomized, double-blind, placebo-controlled trial | 권영주; 전경화 | Article |
| 2022 | An In-Silico Identification of Potential Flavonoids against Kidney Fibrosis Targeting TGF beta R-1 | 권영주 | Article |
| 2021 | AK-I-190, a New Catalytic Inhibitor of Topoisomerase II with Anti-Proliferative and Pro-Apoptotic Activity on Androgen-Negative Prostate Cancer Cells | 권영주; 전경화; 황수연 | Article |
| 2023 | Di-indenopyridines as topoisomerase II-selective anticancer agents: Design, synthesis, and structure–activity relationships | 권영주; 황수연; 박서정 | Article |
| 2023 | Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers | 이화정; 권영주; 전경화; 황수연; 박서정 | Article |
| 2020 | Specific Roles of HSP27 S15 Phosphorylation Augmenting the Nuclear Function of HER2 to Promote Trastuzumab Resistance | 권영주; 이윤실 | Article |
| 2020 | Field-based rational design of p300 histone acetyltransferase inhibitor and systematic evaluation as an anti-fibrotic agent | 권영주 | Article |
| 2021 | Synthesis and structure-activity relationships of hydroxylated and halogenated 2,4-diaryl benzofuro[3,2-b]pyridin-7-ols as selective topoisomerase IIα inhibitors | 권영주 | Article |
| 2021 | COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development | 권영주 | Review |
